Tyra Biosciences stock tumbles 30% on phase 2 trial results By Investing.com - Investing.com India
Source: Investing.com India ·
Tyra Biosciences stock tumbles 30% on phase 2 trial results By Investing.com Investing.com India
BestAIBroker analysis
- Finance-aware sentiment: negative (-0.80 on a -1 to +1 scale).
- Event classification: EARNINGS.
- Market importance score: 44/100, weighting entity relevance, source credibility, multi-outlet coverage and recency.
- Symbols referenced: TYRA.